Contraceptive Drugs Market by Product (Oral Contraceptive Pills, Injectable Contraceptives, and Topical Contraceptives), Age Group (15–24 Years, 25–34 Years, 35–44 Years, and Above 44 Years), and End User (Homecare, Hospitals, and Clinics): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global contraceptive drugs market was evaluated at $14,324.12 million in 2019, and is estimated to garner $24,412.22 million by 2027, registering a CAGR of 6.9% during the forecast period. Contraception, also known as birth control and fertility control, is a method to prevent pregnancy. The drugs used in contraception interfere with the normal process of sperm–ovum fertilization to prevent pregnancy. Contraception involves the use of drugs in the form of oral pills, injectable contraceptives, and topical contraceptives. Increase in concerns about family planning and necessity to prevent unintended pregnancy are some of the major factors driving the growth of the market. Furthermore, upsurge in the usage of contraception among young women accompanied by increase in higher educational attainment promotes the growth of the contraceptive drugs market growth. Moreover, health problems allied with teenage pregnancies, surge in awareness regarding modern contraception methods, and increase in the usage of oral pills as a crucial technique to avert unplanned pregnancy are expected to propel the growth of the market in the years to come. However, health risks associated with the use of contraceptives, accessibility of alternate contraceptive methods, and less social acceptance act as the major restraints of the global market.
The global contraceptive drugs market is segmented into product, age group, end user, and region. Depending on product, the market is categorized into oral (pills), injectable, and topical contraceptives. By age group, it is divided into 15–24 years, 25–34 years, 35–44 years, and above 44 years. On the basis of end user, it is fragmented into homecare, hospitals, and clinics. The global contraceptive drugs market has been analyzed based on four regions, including North America, Europe, Asia-Pacific, and LAMEA.
The report provides a comprehensive analysis of the key players operating in the global contraceptive drugs market, which include Agile Therapeutics, Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Johnson & Johnson, Piramal Healthcare, Mylan N.V., Pfizer Inc., Novartis AG and Teva Pharmaceutical Industries Ltd. Other players operating in the market are HLL Lifecare ltd, and Sanofi.
KEY BENEFITS FOR STAKEHOLDERS
By Product
The global contraceptive drugs market is segmented into product, age group, end user, and region. Depending on product, the market is categorized into oral (pills), injectable, and topical contraceptives. By age group, it is divided into 15–24 years, 25–34 years, 35–44 years, and above 44 years. On the basis of end user, it is fragmented into homecare, hospitals, and clinics. The global contraceptive drugs market has been analyzed based on four regions, including North America, Europe, Asia-Pacific, and LAMEA.
The report provides a comprehensive analysis of the key players operating in the global contraceptive drugs market, which include Agile Therapeutics, Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Johnson & Johnson, Piramal Healthcare, Mylan N.V., Pfizer Inc., Novartis AG and Teva Pharmaceutical Industries Ltd. Other players operating in the market are HLL Lifecare ltd, and Sanofi.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2027, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the global contraceptive drugs market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
By Product
- Oral Contraceptive Pills
- Injectable Contraceptives
- Topical Contraceptives
- 15–24 years
- 25–34 years
- 35–44 years
- Above 44 years
- Homecare
- Hospitals
- Clinics
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- France
- Germany
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Agile Therapeutics
- Allergan
- Bayer AG
- GlaxoSmithKline Plc
- Johnson & Johnson
- Piramal Healthcare
- Mylan N.V.
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key Findings of the Study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Market dynamics
3.3.1.Drivers
3.3.1.1.Rise in need for preventing unwanted pregnancy
3.3.1.2.Increasing awareness for contraceptives worldwide
3.3.1.3.Rising usage of oral contraceptives as a preferred method to avoid unplanned pregnancy
3.3.1.4.Upsurge in government and NGO initiatives promoting contraceptives
3.3.1.5.Increasing awareness about STDs
3.3.2.Restraints
3.3.2.1.Health risks associated with the use of contraceptive methods
3.3.2.2.Lack of social acceptance
3.3.3.Opportunity
3.3.3.1.Rise in disposable income and demand for healthy life in emerging economies
3.3.3.2.Presence of large unmet contraceptive needs in emerging asian and african economies
3.4.COVID Impact on the market
CHAPTER 4:CONTRACEPTIVE DRUGS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Oral contraceptive pills
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Injectable contraceptives
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Topical contraceptives
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
CHAPTER 5:CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP
5.1.Overview
5.1.1.Market size and forecast
5.2.15–24 years
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.25–34 years
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.35–44 years
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.5.Above 44 years
5.5.1.Market size and forecast
5.5.2.Market analysis, by country
CHAPTER 6:CONTRACEPTIVE DRUGS MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Homecare
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Hospitals
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Clinics
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
CHAPTER 7:CONTRACEPTIVE DRUGS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.3.North America contraceptive drugs market by product
7.2.4.North America contraceptive drugs market by age group
7.2.5.North America contraceptive drugs market by end user
7.2.6.U.S.
7.2.6.1.U.S. contraceptive drugs market by product
7.2.6.2.U.S. contraceptive drugs market by age group
7.2.6.3.U.S. contraceptive drugs market by end user
7.2.7.Canada
7.2.7.1.Canada contraceptive drugs market by product
7.2.7.2.Canada contraceptive drugs market by age group
7.2.7.3.Canada contraceptive drugs market by end user
7.2.8.Mexico
7.2.8.1.Mexico contraceptive drugs market by product
7.2.8.2.Mexico contraceptive drugs market by age group
7.2.8.3.Mexico contraceptive drugs market by end user
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by country
7.3.3.Europe contraceptive drugs market by product
7.3.4.Europe contraceptive drugs market by age group
7.3.5.Europe contraceptive drugs market by end user
7.3.6.Germany
7.3.6.1.Germany contraceptive drugs market by product
7.3.6.2.Germany contraceptive drugs market by age group
7.3.6.3.Germany contraceptive drugs market by end user
7.3.7.France
7.3.7.1.France contraceptive drugs market by product
7.3.7.2.France contraceptive drugs market by age group
7.3.7.3.France contraceptive drugs market by end user
7.3.8.UK
7.3.8.1.UK contraceptive drugs market by product
7.3.8.2.UK contraceptive drugs market by age group
7.3.8.3.UK contraceptive drugs market by end user
7.3.9.Rest of Europe
7.3.9.1.Rest of Europe contraceptive drugs market by product
7.3.9.2.Rest of Europe contraceptive drugs market by age group
7.3.9.3.Rest of Europe contraceptive drugs market by end user
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Asia-Pacific contraceptive drugs market by product
7.4.4.Asia-Pacific contraceptive drugs market by age group
7.4.5.Asia-Pacific contraceptive drugs market by end user
7.4.6.Japan
7.4.6.1.Japan contraceptive drugs market by product
7.4.6.2.Japan contraceptive drugs market by age group
7.4.6.3.Japan contraceptive drugs market by end user
7.4.7.China
7.4.7.1.China contraceptive drugs market by product
7.4.7.2.China contraceptive drugs market by age group
7.4.7.3.China contraceptive drugs market by end user
7.4.8.Australia
7.4.8.1.Australia contraceptive drugs market by product
7.4.8.2.Australia contraceptive drugs market by age group
7.4.8.3.Australia contraceptive drugs market by end user
7.4.9.India
7.4.9.1.India contraceptive drugs market by product
7.4.9.2.India contraceptive drugs market by age group
7.4.9.3.India contraceptive drugs market by end user
7.4.10.Rest of Asia-Pacific
7.4.10.1.Rest of Asia-Pacific contraceptive drugs market by product
7.4.10.2.Rest of Asia-Pacific contraceptive drugs market by age group
7.4.10.3.Rest of Asia-Pacific contraceptive drugs market by end user
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by country
7.5.3.LAMEA contraceptive drugs market by product
7.5.4.LAMEA contraceptive drugs market by age group
7.5.5.LAMEA contraceptive drugs market by end user
7.5.6.Brazil
7.5.6.1.Brazil contraceptive drugs market by product
7.5.6.2.Brazil contraceptive drugs market by age group
7.5.6.3.Brazil contraceptive drugs market by end user
7.5.7.Saudi Arabia
7.5.7.1.Saudi Arabia contraceptive drugs market by product
7.5.7.2.Saudi Arabia contraceptive drugs market by age group
7.5.7.3.Saudi Arabia contraceptive drugs market by end user
7.5.8.South Africa
7.5.8.1.South Africa contraceptive drugs market by product
7.5.8.2.South Africa contraceptive drugs market by age group
7.5.8.3.South Africa contraceptive drugs market by end user
7.5.9.Rest of LAMEA
7.5.9.1.Rest of LAMEA contraceptive drugs market by product
7.5.9.2.Rest of LAMEA contraceptive drugs market by age group
7.5.9.3.Rest of LAMEA contraceptive drugs market by end user
CHAPTER 8:COMPANY PROFILES
8.1.Agile Therapeutics
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Business performance
8.2.Allergan Plc.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Business performance
8.3.Bayer AG
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Business performance
8.4.GlaxoSmithKline Plc
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Business performance
8.4.5.Key strategic moves and developments
8.5.Johnson & Johnson
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Business performance
8.5.5.Key strategic moves and developments
8.6.Piramal Healthcare
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Business performance
8.7.Mylan N.V.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Business performance
8.8.Pfizer Inc.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Business performance
8.8.5.Key strategic moves and developments
8.9.Novartis AG
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Business performance
8.9.5.Key strategic moves and developments
8.10.Teva Pharmaceutical Industries Ltd.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Business performance
8.10.5.Key strategic moves and developments
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key Findings of the Study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Market dynamics
3.3.1.Drivers
3.3.1.1.Rise in need for preventing unwanted pregnancy
3.3.1.2.Increasing awareness for contraceptives worldwide
3.3.1.3.Rising usage of oral contraceptives as a preferred method to avoid unplanned pregnancy
3.3.1.4.Upsurge in government and NGO initiatives promoting contraceptives
3.3.1.5.Increasing awareness about STDs
3.3.2.Restraints
3.3.2.1.Health risks associated with the use of contraceptive methods
3.3.2.2.Lack of social acceptance
3.3.3.Opportunity
3.3.3.1.Rise in disposable income and demand for healthy life in emerging economies
3.3.3.2.Presence of large unmet contraceptive needs in emerging asian and african economies
3.4.COVID Impact on the market
CHAPTER 4:CONTRACEPTIVE DRUGS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Oral contraceptive pills
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Injectable contraceptives
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Topical contraceptives
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
CHAPTER 5:CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP
5.1.Overview
5.1.1.Market size and forecast
5.2.15–24 years
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.25–34 years
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.35–44 years
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.5.Above 44 years
5.5.1.Market size and forecast
5.5.2.Market analysis, by country
CHAPTER 6:CONTRACEPTIVE DRUGS MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Homecare
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Hospitals
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Clinics
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
CHAPTER 7:CONTRACEPTIVE DRUGS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.3.North America contraceptive drugs market by product
7.2.4.North America contraceptive drugs market by age group
7.2.5.North America contraceptive drugs market by end user
7.2.6.U.S.
7.2.6.1.U.S. contraceptive drugs market by product
7.2.6.2.U.S. contraceptive drugs market by age group
7.2.6.3.U.S. contraceptive drugs market by end user
7.2.7.Canada
7.2.7.1.Canada contraceptive drugs market by product
7.2.7.2.Canada contraceptive drugs market by age group
7.2.7.3.Canada contraceptive drugs market by end user
7.2.8.Mexico
7.2.8.1.Mexico contraceptive drugs market by product
7.2.8.2.Mexico contraceptive drugs market by age group
7.2.8.3.Mexico contraceptive drugs market by end user
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by country
7.3.3.Europe contraceptive drugs market by product
7.3.4.Europe contraceptive drugs market by age group
7.3.5.Europe contraceptive drugs market by end user
7.3.6.Germany
7.3.6.1.Germany contraceptive drugs market by product
7.3.6.2.Germany contraceptive drugs market by age group
7.3.6.3.Germany contraceptive drugs market by end user
7.3.7.France
7.3.7.1.France contraceptive drugs market by product
7.3.7.2.France contraceptive drugs market by age group
7.3.7.3.France contraceptive drugs market by end user
7.3.8.UK
7.3.8.1.UK contraceptive drugs market by product
7.3.8.2.UK contraceptive drugs market by age group
7.3.8.3.UK contraceptive drugs market by end user
7.3.9.Rest of Europe
7.3.9.1.Rest of Europe contraceptive drugs market by product
7.3.9.2.Rest of Europe contraceptive drugs market by age group
7.3.9.3.Rest of Europe contraceptive drugs market by end user
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Asia-Pacific contraceptive drugs market by product
7.4.4.Asia-Pacific contraceptive drugs market by age group
7.4.5.Asia-Pacific contraceptive drugs market by end user
7.4.6.Japan
7.4.6.1.Japan contraceptive drugs market by product
7.4.6.2.Japan contraceptive drugs market by age group
7.4.6.3.Japan contraceptive drugs market by end user
7.4.7.China
7.4.7.1.China contraceptive drugs market by product
7.4.7.2.China contraceptive drugs market by age group
7.4.7.3.China contraceptive drugs market by end user
7.4.8.Australia
7.4.8.1.Australia contraceptive drugs market by product
7.4.8.2.Australia contraceptive drugs market by age group
7.4.8.3.Australia contraceptive drugs market by end user
7.4.9.India
7.4.9.1.India contraceptive drugs market by product
7.4.9.2.India contraceptive drugs market by age group
7.4.9.3.India contraceptive drugs market by end user
7.4.10.Rest of Asia-Pacific
7.4.10.1.Rest of Asia-Pacific contraceptive drugs market by product
7.4.10.2.Rest of Asia-Pacific contraceptive drugs market by age group
7.4.10.3.Rest of Asia-Pacific contraceptive drugs market by end user
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by country
7.5.3.LAMEA contraceptive drugs market by product
7.5.4.LAMEA contraceptive drugs market by age group
7.5.5.LAMEA contraceptive drugs market by end user
7.5.6.Brazil
7.5.6.1.Brazil contraceptive drugs market by product
7.5.6.2.Brazil contraceptive drugs market by age group
7.5.6.3.Brazil contraceptive drugs market by end user
7.5.7.Saudi Arabia
7.5.7.1.Saudi Arabia contraceptive drugs market by product
7.5.7.2.Saudi Arabia contraceptive drugs market by age group
7.5.7.3.Saudi Arabia contraceptive drugs market by end user
7.5.8.South Africa
7.5.8.1.South Africa contraceptive drugs market by product
7.5.8.2.South Africa contraceptive drugs market by age group
7.5.8.3.South Africa contraceptive drugs market by end user
7.5.9.Rest of LAMEA
7.5.9.1.Rest of LAMEA contraceptive drugs market by product
7.5.9.2.Rest of LAMEA contraceptive drugs market by age group
7.5.9.3.Rest of LAMEA contraceptive drugs market by end user
CHAPTER 8:COMPANY PROFILES
8.1.Agile Therapeutics
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Business performance
8.2.Allergan Plc.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Business performance
8.3.Bayer AG
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Business performance
8.4.GlaxoSmithKline Plc
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Business performance
8.4.5.Key strategic moves and developments
8.5.Johnson & Johnson
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Business performance
8.5.5.Key strategic moves and developments
8.6.Piramal Healthcare
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Business performance
8.7.Mylan N.V.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Business performance
8.8.Pfizer Inc.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Business performance
8.8.5.Key strategic moves and developments
8.9.Novartis AG
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Business performance
8.9.5.Key strategic moves and developments
8.10.Teva Pharmaceutical Industries Ltd.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Business performance
8.10.5.Key strategic moves and developments
LIST OF TABLES
TABLE 01.CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 02.CONTRACEPTIVE DRUGS MARKET FOR ORAL CONTRACEPTIVES, BY REGION, 2019–2027 ($MILLION)
TABLE 03.CONTRACEPTIVE DRUGS MARKET FOR INJECTABLE CONTRACEPTIVES, BY REGION, 2019–2027 ($MILLION)
TABLE 04.CONTRACEPTIVE DRUGS MARKET FOR TOPICAL CONTRACEPTIVES, BY REGION, 2019–2027 ($MILLION)
TABLE 05.CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019–2027 ($MILLION)
TABLE 06.CONTRACEPTIVE DRUGS MARKET FOR 15–24 YEARS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.CONTRACEPTIVE DRUGS MARKET FOR 25–34 YEARS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.CONTRACEPTIVE DRUGS MARKET FOR 35–44 YEARS, BY REGION, 2019–2027 ($MILLION)
TABLE 09.CONTRACEPTIVE DRUGS MARKET FOR ABOVE 44 YEARS, BY REGION, 2019–2027 ($MILLION)
TABLE 10.CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 11.CONTRACEPTIVE DRUGS MARKET FOR HOMECARE, BY REGION, 2019–2027 ($MILLION)
TABLE 12.CONTRACEPTIVE DRUGS MARKET FOR HOSPITALS, BY REGION, 2019–2027 ($MILLION)
TABLE 13.CONTRACEPTIVE DRUGS MARKET FOR CLINICS, BY REGION, 2019–2027 ($MILLION)
TABLE 14.CONTRACEPTIVE DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 15.NORTH AMERICA CONTRACEPTIVE DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 16.NORTH AMERICA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 17.NORTH AMERICA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 18.NORTH AMERICA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 19.U.S. CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 20.U.S. CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 21.U.S. CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 22.CANADA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 23.CANADA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 24.CANADA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 25.MEXICO CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 26.MEXICO CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 27.MEXICO CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 28.EUROPE CONTRACEPTIVE DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 29.EUROPE CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 30.EUROPE CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 31.EUROPE CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 32.GERMANY CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 33.GERMANY CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 34.GERMANY CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 35.FRANCE CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 36.FRANCE CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 37.FRANCE CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 38.UK CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 39.UK CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 40.UK CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 41.REST OF EUROPE CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 42.REST OF EUROPE CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 43.REST OF EUROPE CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 44.ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 45.ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 46.ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 47.ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 48.JAPAN CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 49.JAPAN CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 50.JAPAN CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 51.CHINA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 52.CHINA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 53.CHINA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 54.AUSTRALIA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 55.AUSTRALIA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 56.AUSTRALIA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 57.INDIA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 58.INDIA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 59.INDIA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 60.REST OF ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 61.REST OF ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 62.REST OF ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 63.LAMEA CONTRACEPTIVE DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 64.LAMEA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 65.LAMEA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 66.LAMEA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 67.BRAZIL CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 68.BRAZIL CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 69.BRAZIL CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 70.SAUDI ARABIA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 71.SAUDI ARABIA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 72.SAUDI ARABIA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 73.SOUTH AFRICA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 74.SOUTH AFRICA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 75.SOUTH AFRICA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 76.REST OF LAMEA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 77.REST OF LAMEA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 78.REST OF LAMEA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 79.AGILE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 80.AGILE THERAPEUTICS: OPERATING SEGMENTS
TABLE 81.ALLERGAN: COMPANY SNAPSHOT
TABLE 82.ALLERGAN: OPERATING SEGMENTS
TABLE 83.BAYER: COMPANY SNAPSHOT
TABLE 84.BAYER: OPERATING SEGMENTS
TABLE 85.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 86.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 87.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 88.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 89.PIRAMAL HEALTHCARE: COMPANY SNAPSHOT
TABLE 90.PIRAMAL HEALTHCARE: OPERATING SEGMENTS
TABLE 91.MYLAN: COMPANY SNAPSHOT
TABLE 92.MYLAN: OPERATING SEGMENTS
TABLE 93.PFIZER: COMPANY SNAPSHOT
TABLE 94.PFIZER: OPERATING SEGMENTS
TABLE 95.NOVARTIS: COMPANY SNAPSHOT
TABLE 96.NOVARTIS: OPERATING SEGMENTS
TABLE 97.TEVA: COMPANY SNAPSHOT
TABLE 98.TEVA: OPERATING SEGMENTS
TABLE 01.CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 02.CONTRACEPTIVE DRUGS MARKET FOR ORAL CONTRACEPTIVES, BY REGION, 2019–2027 ($MILLION)
TABLE 03.CONTRACEPTIVE DRUGS MARKET FOR INJECTABLE CONTRACEPTIVES, BY REGION, 2019–2027 ($MILLION)
TABLE 04.CONTRACEPTIVE DRUGS MARKET FOR TOPICAL CONTRACEPTIVES, BY REGION, 2019–2027 ($MILLION)
TABLE 05.CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019–2027 ($MILLION)
TABLE 06.CONTRACEPTIVE DRUGS MARKET FOR 15–24 YEARS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.CONTRACEPTIVE DRUGS MARKET FOR 25–34 YEARS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.CONTRACEPTIVE DRUGS MARKET FOR 35–44 YEARS, BY REGION, 2019–2027 ($MILLION)
TABLE 09.CONTRACEPTIVE DRUGS MARKET FOR ABOVE 44 YEARS, BY REGION, 2019–2027 ($MILLION)
TABLE 10.CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 11.CONTRACEPTIVE DRUGS MARKET FOR HOMECARE, BY REGION, 2019–2027 ($MILLION)
TABLE 12.CONTRACEPTIVE DRUGS MARKET FOR HOSPITALS, BY REGION, 2019–2027 ($MILLION)
TABLE 13.CONTRACEPTIVE DRUGS MARKET FOR CLINICS, BY REGION, 2019–2027 ($MILLION)
TABLE 14.CONTRACEPTIVE DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 15.NORTH AMERICA CONTRACEPTIVE DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 16.NORTH AMERICA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 17.NORTH AMERICA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 18.NORTH AMERICA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 19.U.S. CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 20.U.S. CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 21.U.S. CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 22.CANADA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 23.CANADA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 24.CANADA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 25.MEXICO CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 26.MEXICO CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 27.MEXICO CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 28.EUROPE CONTRACEPTIVE DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 29.EUROPE CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 30.EUROPE CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 31.EUROPE CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 32.GERMANY CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 33.GERMANY CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 34.GERMANY CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 35.FRANCE CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 36.FRANCE CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 37.FRANCE CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 38.UK CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 39.UK CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 40.UK CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 41.REST OF EUROPE CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 42.REST OF EUROPE CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 43.REST OF EUROPE CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 44.ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 45.ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 46.ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 47.ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 48.JAPAN CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 49.JAPAN CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 50.JAPAN CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 51.CHINA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 52.CHINA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 53.CHINA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 54.AUSTRALIA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 55.AUSTRALIA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 56.AUSTRALIA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 57.INDIA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 58.INDIA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 59.INDIA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 60.REST OF ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 61.REST OF ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 62.REST OF ASIA-PACIFIC CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 63.LAMEA CONTRACEPTIVE DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
TABLE 64.LAMEA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 65.LAMEA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 66.LAMEA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 67.BRAZIL CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 68.BRAZIL CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 69.BRAZIL CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 70.SAUDI ARABIA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 71.SAUDI ARABIA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 72.SAUDI ARABIA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 73.SOUTH AFRICA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 74.SOUTH AFRICA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 75.SOUTH AFRICA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 76.REST OF LAMEA CONTRACEPTIVE DRUGS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 77.REST OF LAMEA CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP, 2019-2027 ($MILLION)
TABLE 78.REST OF LAMEA CONTRACEPTIVE DRUGS MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 79.AGILE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 80.AGILE THERAPEUTICS: OPERATING SEGMENTS
TABLE 81.ALLERGAN: COMPANY SNAPSHOT
TABLE 82.ALLERGAN: OPERATING SEGMENTS
TABLE 83.BAYER: COMPANY SNAPSHOT
TABLE 84.BAYER: OPERATING SEGMENTS
TABLE 85.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 86.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 87.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 88.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 89.PIRAMAL HEALTHCARE: COMPANY SNAPSHOT
TABLE 90.PIRAMAL HEALTHCARE: OPERATING SEGMENTS
TABLE 91.MYLAN: COMPANY SNAPSHOT
TABLE 92.MYLAN: OPERATING SEGMENTS
TABLE 93.PFIZER: COMPANY SNAPSHOT
TABLE 94.PFIZER: OPERATING SEGMENTS
TABLE 95.NOVARTIS: COMPANY SNAPSHOT
TABLE 96.NOVARTIS: OPERATING SEGMENTS
TABLE 97.TEVA: COMPANY SNAPSHOT
TABLE 98.TEVA: OPERATING SEGMENTS
LIST OF FIGURES
FIGURE 01.CONTRACEPTIVE DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MARKET DYNAMICS: CONTRCEPTIVE DRUGS MARKET
FIGURE 04.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR ORAL CONTRACEPTIVES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 05.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 06.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR TOPICAL CONTRACEPTIVES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 07.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR 15–24 YEARS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 08.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR 25–34 YEARS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR 35–44 YEARS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR ABOVE 44 YEARS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR HOMECARE, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR CLINICS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 14.CANCER SURVIVOR PREDICTIONS IN U.S.
FIGURE 15.CANCER INCIDENCES IN GERMANY (2007 & 2050)
FIGURE 16.AGILE THERAPEUTICS: NET SALES, 2017–2019 ($MILLION)
FIGURE 17.AGILE THERAPEUTICS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 18.AGILE THERAPEUTICS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 19.ALLERGAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 20.ALLERGAN: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 21.ALLERGAN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 22.BAYER: NET SALES, 2017–2019 ($MILLION)
FIGURE 23.BAYER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 24.BAYER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 25.GLAXOSMITHKLINE PLC: NET SALES, 2017–2019 ($MILLION)
FIGURE 26.GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 27.GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 28.JOHNSON & JOHNSON: NET SALES, 2017–2019 ($MILLION)
FIGURE 29.JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 30.JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 31.PIRAMAL HEALTHCARE: NET SALES, 2017–2019 ($MILLION)
FIGURE 32.PIRAMAL HEALTHCARE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 33.PIRAMAL HEALTHCARE: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 34.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 35.MYLAN: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 36.MYLAN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 37.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 38.PFIZER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 39.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 40.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 42.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 43.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.TEVA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 45.TEVA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 01.CONTRACEPTIVE DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MARKET DYNAMICS: CONTRCEPTIVE DRUGS MARKET
FIGURE 04.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR ORAL CONTRACEPTIVES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 05.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 06.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR TOPICAL CONTRACEPTIVES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 07.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR 15–24 YEARS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 08.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR 25–34 YEARS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR 35–44 YEARS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR ABOVE 44 YEARS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR HOMECARE, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF CONTRACEPTIVE DRUGS MARKET FOR CLINICS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 14.CANCER SURVIVOR PREDICTIONS IN U.S.
FIGURE 15.CANCER INCIDENCES IN GERMANY (2007 & 2050)
FIGURE 16.AGILE THERAPEUTICS: NET SALES, 2017–2019 ($MILLION)
FIGURE 17.AGILE THERAPEUTICS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 18.AGILE THERAPEUTICS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 19.ALLERGAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 20.ALLERGAN: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 21.ALLERGAN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 22.BAYER: NET SALES, 2017–2019 ($MILLION)
FIGURE 23.BAYER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 24.BAYER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 25.GLAXOSMITHKLINE PLC: NET SALES, 2017–2019 ($MILLION)
FIGURE 26.GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 27.GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 28.JOHNSON & JOHNSON: NET SALES, 2017–2019 ($MILLION)
FIGURE 29.JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 30.JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 31.PIRAMAL HEALTHCARE: NET SALES, 2017–2019 ($MILLION)
FIGURE 32.PIRAMAL HEALTHCARE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 33.PIRAMAL HEALTHCARE: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 34.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 35.MYLAN: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 36.MYLAN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 37.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 38.PFIZER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 39.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 40.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 42.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 43.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.TEVA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 45.TEVA: REVENUE SHARE BY REGION, 2019 (%)
